GT Biopharma Enters Material Definitive Agreement
Ticker: GTBP · Form: 8-K · Filed: Apr 30, 2024 · CIK: 109657
Sentiment: neutral
Topics: material-definitive-agreement, corporate-actions
TL;DR
GT Biopharma signed a big deal on 4/25, filing shows.
AI Summary
GT Biopharma, Inc. entered into a Material Definitive Agreement on April 25, 2024. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Delaware and its principal business address is in Brisbane, California.
Why It Matters
This filing indicates a significant new agreement for GT Biopharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement is a significant event that carries inherent risks and potential rewards, making the risk level medium.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- April 25, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Brisbane, CA (location) — Business Address
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
FAQ
What is the nature of the Material Definitive Agreement entered into by GT Biopharma, Inc.?
The filing states that GT Biopharma, Inc. entered into a Material Definitive Agreement on April 25, 2024, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 25, 2024.
In which state is GT Biopharma, Inc. incorporated?
GT Biopharma, Inc. is incorporated in Delaware.
What is the business address of GT Biopharma, Inc.?
The business address of GT Biopharma, Inc. is 8000 Marina Blvd., Suite 100, Brisbane, CA 94005.
What were some of GT Biopharma, Inc.'s former company names?
GT Biopharma, Inc. was formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-04-30 15:26:51
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex10-1.htm (EX-10.1) — 27KB
- 0001493152-24-017209.txt ( ) — 239KB
- gtbp-20240425.xsd (EX-101.SCH) — 3KB
- gtbp-20240425_lab.xml (EX-101.LAB) — 33KB
- gtbp-20240425_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: April 30, 2024 By: /s/ Manu Ohri Manu Ohri Chief Financial Officer